

INDEPENDENT AUDITOR'S REPORT

To the Members of Veeda Clinical Research Private Limited

Report on the Audit of the Standalone Financial Statements**Opinion**

We have audited the accompanying standalone financial statements of Veeda Clinical Research Private Limited ("the Company"), which comprise the Balance sheet as at March 31 2019, the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (herein after referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2019, its profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Other Information

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the director's report, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Responsibilities of the Management for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Companies (Accounting Standards) Rules, 2006 (as amended) specified under section 133 of the Act, read with the Companies (Accounts) Rules, 2014 (as amended). This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- ▶ Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to



Auditor's Responsibilities for the Audit of the Standalone Financial Statements (continued)

continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- ▶ Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide Board of Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The financial statements of the Company for the year ended March 31, 2018, included in these standalone financial statements, have been audited by the predecessor auditor who expressed an unmodified opinion on those statements on June 15, 2018.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure 1" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Companies (Accounting Standards) Rules, 2006 (as amended) specified under section 133 of the Act, read with the Companies (Accounts) Rules, 2014 (as amended);
 - (e) On the basis of the written representations received from the directors as on March 31, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2019 from being appointed as a director in terms of Section 164 (2) of the Act;
 - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company with reference to these standalone financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure 2" to this report;



S R B C & CO LLP

Chartered Accountants

Report on Other Legal and Regulatory Requirements (continued)

- (g) The provisions of section 197 read with Schedule V of the Act are not applicable to the Company for the year ended March 31, 2019 and
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements - Refer Note 29 to the standalone financial statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses and
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

per Sukrut Mehta

Partner

Membership Number: 101974

UDIN: 19101974AAAABB8240

Place of Signature: Ahmedabad

Date: July 25, 2019



Annexure 1 referred to in Paragraph of Report on Other Legal and Regulatory Requirements of our report of even date of Veeda Clinical Research Private Limited for the year ended March 31, 2019.

- i. (a) The Company has maintained proper records showing full, including quantitative details and situation of property, plant and equipment.

(b) All property, plant and equipment have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

(c) According to the information and explanations given by the management, there are no immovable properties, included in property, plant and equipment of the company and accordingly, the requirements under paragraph 3(i)(c) of the Order are not applicable to the Company.
- ii. The management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies were noticed on such physical verification.
- iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013. Accordingly, the provisions of clause 3(iii) (a), (b) and (c) of the Order are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, provisions of section 185 and 186 of the Companies Act 2013 in respect of loans to directors including entities in which they are interested and in respect of loans and advances given, investments made and, guarantees, and securities given have been complied with by the company.
- v. The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable and hence not commented upon.
- vi. To the best of our knowledge and as explained, the Company is not in the business of sale of any goods. Therefore, in our opinion, the provisions of clause 3(vi) of the Order are not applicable to the Company.
- vii. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including provident fund, employees' state insurance, income-tax, duty of custom, goods and service tax, professional tax, cess and other statutory dues are generally regularly deposited with the appropriate authorities though there has been a slight delay in a few cases.



S R B C & CO LLP

Chartered Accountants

(b) According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, duty of custom, goods and service tax, professional tax, cess and other statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.

(c) The dues of income-tax, sales-tax, service tax, duty of custom, duty of excise, value added tax and cess on account of any dispute, are as follows:

| Name of statute | Nature of dues | Amount involved (excluding interest and penalty) | Period to which the amount relates | Forum where the dispute is pending |
|-------------------|----------------|--|------------------------------------|------------------------------------|
| Finance Act, 1994 | Service tax | 13,06,380 | 2008-09 | CESTAT, Ahmedabad |
| Finance Act, 1994 | Service tax | 1,41,506 | 2010-11 to 2013-14 | CESTAT, Ahmedabad |
| Finance Act, 1994 | Service tax | 2,43,36,757 | July 2012 to March 2014 | CESTAT, Ahmedabad |
| Finance Act, 1994 | Service tax | 5,29,94,448 | 2015-16 | Commissioner (appeals) |
| Finance Act, 1994 | Service tax | 4,56,43,931 | 2007-08 to 2011-12 | Commissioner (appeals) |
| Finance Act, 1994 | Service tax | 2,61,88,870 | 2014-15 | Commissioner |
| Finance Act, 1994 | Service tax | 7,14,547 | 2015-16 | Assistant Commissioner |
| Finance Act, 1994 | Service tax | 67,72,872 | 2014-15 | CESTAT, Ahmedabad |
| Customs Act, 1962 | Custom duty | 27,86,250 | 2011-12 to 2013-14 | Commissioner |
| Customs Act, 1962 | Custom duty | 19,65,359 | 2013-2014 to 2016-17 | Commissioner |

viii. In our opinion and according to the information and explanations given by the management, the Company has not defaulted in repayment of loans or borrowings to financial institutions and banks. The Company did not have any due payable to debenture holders and government during the year.

ix. According to the information and explanations given by the management, the Company has not raised money by way of initial public offer, further public offer, debt instruments and term loans hence, reporting under clause (ix) is not applicable to the Company and hence not commented upon



S R B C & CO LLP


Chartered Accountants

- x. Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no fraud by the Company or no fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.
- xi. According to the information and explanations given by the management, the provisions of section 197 read with Schedule V of the Act are not applicable to the company and hence reporting under clause 3(xi) are not applicable and hence not commented upon.
- xii. In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xii) of the order are not applicable to the Company and hence not commented upon.
- xiii. According to the information and explanations given by the management, transactions with the related parties are in compliance with section 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards. The provision for Section 177 are not applicable to the Company and accordingly reporting under clause 3(xiii) insofar as it relates to Section 177 of the Act is not applicable to the Company and hence not commented upon.
- xiv. According to the information and explanations given to us and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence, reporting requirements under clause 3(xiv) are not applicable to the Company and, not commented upon.
- xv. According to the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in section 192 of the Act.
- xvi. According to the information and explanations given to us, the provisions of section 45-IA of the Reserve Bank of India Act, 1934 are not applicable to the Company.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003



per Sukrut Mehta

Partner

Membership Number: 101974

UDIN: 19101974AAAABB8240

Place of Signature: Ahmedabad

Date: July 25, 2019



S R B C & CO LLP

Chartered Accountants

Annexure 2 to the Independent Auditor's report of even date on the financial statements of Veeda Clinical Research Private Limited

Report on the Internal Financial Controls under Clause (I) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting with reference to the financial statement of Veeda Research Clinical Private Limited ("the Company") as of March 31, 2019 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting with reference to the financial statement based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing as specified under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting with reference to the financial statement was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls over financial reporting with reference to the financial statement.



S R B C & CO LLP

Chartered Accountants

Meaning of Internal Financial Controls Over Financial Reporting with reference to these financial statement

A company's internal financial control over financial reporting with reference to the financial statement is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting with reference to the financial statement includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting with reference to the financial statement

Because of the inherent limitations of internal financial controls over financial reporting with reference to the financial statement, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to the financial statement to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls over financial reporting with reference to the financial statement and such internal financial controls over financial reporting were operating effectively as at March 31, 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003



per Sukrut Mehta

Partner

Membership Number: 101974

UDIN: 19101974AAAABB8240

Place of Signature: Ahmedabad

Date: July 25, 2019



Veeda Clinical Research Private Limited
Standalone Balance Sheet as at March 31, 2019

(Amount in Rs.)

| Particulars | Note No. | As at March 31, 2019 | As at March 31, 2018 |
|--|----------|----------------------|----------------------|
| I. EQUITY AND LIABILITIES | | | |
| Shareholders' funds | | | |
| Share capital | 3 | 358,169,430 | 175,877,870 |
| Reserves and surplus | 4 | 536,933,294 | 674,080,039 |
| Non-current liabilities | | | |
| Long-term borrowings | 5 | - | 99,952,635 |
| Other long-term liabilities | 6 | 22,113,271 | 15,433,687 |
| Long-term provisions | 7 | 20,797,446 | 15,282,495 |
| Current liabilities | | | |
| Short-term borrowings | 8 | 48,842,890 | - |
| Trade payables | 9 | | |
| (A) total outstanding dues of micro enterprises and small enterprises | | 17,209,552 | 22,680 |
| (B) total outstanding dues of creditors other than micro enterprises and small enterprises | | 94,896,835 | 79,210,020 |
| Other current liabilities | 10 | 226,830,493 | 235,442,498 |
| Short-term provisions | 11 | 10,468,138 | 7,126,126 |
| TOTAL | | 1,336,261,349 | 1,302,428,050 |
| II. ASSETS | | | |
| Non-current assets | | | |
| Property, plant & equipment | | 374,338,975 | 435,324,153 |
| Intangible assets | 12 | 3,192,341 | 3,913,800 |
| Capital work-in-progress | | 74,101,729 | 3,867,658 |
| Intangible assets under development | | 3,255,200 | 2,040,125 |
| Non-current investments | 13 | - | 1,429,633 |
| Deferred tax assets | 14 | 44,603,923 | 45,600,139 |
| Long term loans and advances | 15 | 104,300,199 | 252,078,058 |
| Other non-current assets | 16 | 4,032,275 | 4,296,478 |
| Current assets | | | |
| Current Investments | 17 | 17,714,953 | 26,087,021 |
| Inventories | 18 | 47,323,626 | 49,786,042 |
| Trade receivables | 19 | 436,269,402 | 375,641,817 |
| Cash and bank balances | 20 | 201,157,908 | 81,324,967 |
| Short-term loans and advances | 21 | 23,357,790 | 11,899,100 |
| Other current assets | 22 | 2,613,028 | 9,139,059 |
| TOTAL | | 1,336,261,349 | 1,302,428,050 |
| Summary of significant accounting policies | 2 | | |
| The accompanying notes are an integral part of the financial statements. | | | |

As per our report of even date
For SRBC & Co. LLP
Chartered Accountants
ICAI FRN: 324982E/E300003

per Sukrut Mehta
Partner
Membership No. 101974
UDIN: 19101974AAAABB8240

For and on Behalf of the Board of Directors of
Veeda Clinical Research Private Limited
(CIN : U73100GJ2004PTC044023)

Vivek Chhachhi
Director
DIN: 00496620

Ajay Tandon
Executive Director
DIN: 02210072

Nirmal Bhatia
Company Secretary

Place : Ahmedabad
Date : July 25, 2019

Place : Delhi
Date : July 25, 2019

Delhi
July 25, 2019

Ahmedabad
July 25, 2019




Veeda Clinical Research Private Limited

Statement of Standalone Profit & Loss for the Year ended March 31, 2019

(Amount in Rs.)

| Sr. No. | Particulars | Note No. | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---------|--|----------|---------------------------|---------------------------|
| (I) | Revenue from operations | 23 | 2,184,443,017 | 1,824,538,651 |
| (II) | Other income | 24 | 53,375,325 | 7,774,738 |
| (III) | Total Revenue (I+ II) | | 2,237,818,342 | 1,832,313,389 |
| (IV) | Expenses | | | |
| | Cost of material consumed | 25 | 143,335,371 | 154,685,979 |
| | Employee benefit expenses | 26 | 461,838,493 | 354,841,613 |
| | Finance costs | 27 | 23,849,385 | 26,961,496 |
| | Depreciation and amortization expenses | 12 | 94,389,657 | 105,818,970 |
| | Other expenses | 28 | 756,202,663 | 712,311,859 |
| | Total Expenses | | 1,479,615,569 | 1,354,619,917 |
| (V) | Profit before tax (III-IV) | | 758,202,773 | 477,693,472 |
| (VI) | Tax expense | | | |
| | (1) Current tax | | 231,000,000 | 183,800,000 |
| | (2) Deferred tax | | 996,216 | (15,215,908) |
| | Total tax expense | | 231,996,216 | 168,584,092 |
| (VII) | Profit for the year (V-VI) | | 526,206,557 | 309,109,380 |
| (VIII) | Earnings per equity share [Nominal value of Rs. 10 (March 31, 2018: Rs. 10)] | 30 | | |
| | Basic | | 902.80 | 504.30 |
| | Diluted | | 799.03 | 446.21 |
| | Summary of significant accounting policies | 2 | | |
| | The accompanying notes are an integral part of the financial statements. | | | |

As per our report of even date
For SRBC & Co. LLP
Chartered Accountants
ICAI FRN: 324982E/E300003


per Sukrut Mehta
Partner

Membership No. 101974
UDIN: 19101974AAAABB8240

Place : Ahmedabad
Date : July 25, 2019

For and on Behalf of the Board of Directors of
Veeda Clinical Research Private Limited
(CIN : U73100GJ2004PTC044023)


Vivek Chhachhi
Director
DIN: 00496620


Ajay Tandon
Executive Director
DIN: 02210072


Nirmal Bhatia
Company Secretary



Ahmedabad
July 25, 2019



Veeda Clinical Research Private Limited
Standalone Cash Flow Statement for the year ended March 31, 2019

(Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|--|---------------------------|---------------------------|
| A. Cash flow from operating activities | | |
| Profit before tax | 758,202,773 | 477,693,472 |
| Adjustment to reconcile profit before tax to net cash flows | | |
| Depreciation | 94,389,657 | 105,818,970 |
| Finance cost | 23,849,385 | 26,961,496 |
| Interest Income | (5,233,993) | (3,741,927) |
| (Gain) / loss on sale of mutual fund (net) | (6,235,061) | 212,979 |
| Gain on sale of non-current investment | (906,126) | - |
| (Profit) / Loss on sale of property, plant and equipment | (2,723) | 183,227 |
| Credit balance written back | (35,526,035) | - |
| Discount | 7,591,845 | - |
| Unrealized foreign exchange loss | 4,501,592 | - |
| Operating profit before working capital changes | 840,631,314 | 607,128,218 |
| Movements in working capital : | | |
| (Increase) in trade receivables | (74,721,718) | (158,481,007) |
| Decrease / (Increase) in inventories | 2,462,416 | (7,455,829) |
| Decrease / (Increase) in long term loans and advances | 147,064,626 | (32,916,880) |
| (Increase) in short term loans and advances | (11,458,690) | (650,942) |
| Increase in current assets | 4,371,967 | 28,854,901 |
| Increase in non-current assets | 182,299 | - |
| Increase in other non-current liabilities and long-term provisions | 12,194,535 | 11,547,554 |
| Increase / (Decrease) in other current liabilities, short term provisions and trade payables | 61,849,800 | (26,573,546) |
| Cash generated from operation | 982,576,549 | 421,452,469 |
| Direct taxes paid | (230,286,765) | (172,565,419) |
| Net cash flow from operating activities (A) | 752,289,784 | 248,887,050 |
| B. Cash flow from investing activities | | |
| Purchase of property, plant and equipment | (101,154,396) | (93,968,712) |
| Proceeds from sale of property, plant and equipment | 4,100 | 215,000 |
| Interest received | 4,388,057 | 3,912,368 |
| Investment in fixed deposits (net) | (9,518,095) | (474,158) |
| Proceeds from sale of / (Investment in) mutual funds (net) | 17,607,129 | (29,300,000) |
| Proceeds from sale of non-current investment | 2,335,759 | - |
| Net cash flow used in investing activities (B) | (86,337,446) | (119,615,502) |
| C. Cash flow from financing activities | | |
| Repayment of long-term borrowing | (100,369,894) | (29,911,603) |
| Finance cost paid | (24,287,761) | (26,961,496) |
| Proceeds from / (Repayment of) short-term borrowing | 50,000,000 | (7,775,703) |
| Buy back of preference share capital (Including tax of buy back) | (168,400,000) | - |
| Dividend paid on preference share capital (Including DDT) | (312,661,742) | - |
| Net Cash flow used in financing activities (C) | (555,719,397) | (64,648,802) |
| Net Increase in cash and cash equivalents (A + B + C) | 110,232,941 | 64,622,746 |
| Cash and cash equivalents at the beginning of the year | 66,324,967 | 1,702,221 |
| Cash and cash equivalents at the end of the year | 176,557,908 | 66,324,967 |
| Components of cash and cash equivalent | | |
| Cash on hand | 2,927,759 | 1,147,273 |
| Balance with banks: | | |
| -On Current Accounts and Cash Credit Accounts | 108,630,149 | 65,177,694 |
| -Deposits with original maturity of less than three months | 65,000,000 | - |
| Total cash and cash equivalent (refer note 20) | 176,557,908 | 66,324,967 |
| The accompanying notes are an integral part of the financial statements. | | |
| Note: The above Standalone Statement of Cash flow has been prepared under the 'Indirect Method' as set out in AS 3, 'Statement of Cash Flows'. | | |

As per our report of even date
For SRBC & Co. LLP
Chartered Accountants
ICAI FRN: 324982E/E300003

Sukrut Mehta
per Sukrut Mehta
Partner

Membership No. 101974
UDIN: 19101974AAAAAB8240

Place : Ahmedabad
Date : July 25, 2019

For and on Behalf of the Board of Directors of
Veeda Clinical Research Private Limited
(CIN : U73100GJ2004PTC044023)

Vivek Chhachhi
Vivek Chhachhi
Director
DIN: 00496620

Ajay Tandon
Ajay Tandon
Executive Director
DIN: 02210072

N.A. Bhatia
Nirmal Bhatia
Company Secretary

Ahmedabad
July 25, 2019



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

1. Corporate Information

Veeda Clinical Research Private Limited is a Private Limited Company domiciled in India with its registered office in Ahmedabad, Gujarat, India. The Company was incorporated on April 23, 2004 and is carrying on the business of Clinical Research for various Pharmaceuticals Companies. The Company is a one roof service global CRO specializing in the early clinical development of drugs with state-of-the-art facilities in India. The Company provides a full range of services in phase I and II clinical research with Clinical Data management, delivering expert and cost effective research solutions to the Pharmaceutical and Biotechnology Industries worldwide.

2. Summary of significant accounting policies

The significant accounting policies applied by the Company in the preparation of its financial statements are listed below.

i. Basis of Accounting

The financial statements of the company have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The company has prepared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013 read together with the Companies (Accounting Standards) Amendment Rules, 2006 (as amended from time to time). The financial statements have been prepared on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

ii. Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

iii. Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognized:



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

a. Income from services

Revenues from contracts are recognized pro-rata over the period of the contract as and when services are rendered. The company collects goods and service tax / service tax on behalf of the government and, therefore, it is not an economic benefit flowing to the company. Hence, it is excluded from revenue.

b. Interest Income

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss

c. Export incentive income

Income from export incentive is recognised considering the company's ability of filing the application based on certainty of receipt and estimating the amount.

iv. Inventories

Consumables are valued at lower of cost and net realizable value. Cost of consumables is determined on an FIFO basis.

v. Property, plant and equipment

Property, plant and equipment, capital work in progress are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met, directly attributable cost of bringing the asset to its working condition for the intended use and initial estimate of decommissioning, restoring and similar liabilities. Any trade discounts and rebates are deducted in arriving at the purchase price. Such cost includes the cost of replacing part of the plant and equipment. When significant parts of property, plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in statement of profit or loss as incurred.

Items of stores and spares that meet the definition of property, plant and equipment are capitalized at cost and depreciated over their useful life. Otherwise, such items are classified as inventories.

Gains or losses arising from derecognition of property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

The company identifies and determines cost of each component/ part of the asset separately, if the component/ part has a cost which is significant to the total cost of the asset and has useful life that is materially different from that of the remaining asset.



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

Property, plant and equipment held for sale is valued at lower of their carrying amount and net realizable value. Any write-down is recognized in the statement of profit and loss.

Depreciation on property, plant and equipment

Leasehold improvements are amortized on a straight line basis over the period of lease.

Depreciation is provided on the written down value method over the useful lives as prescribed under Part C of Schedule II of the Companies Act, 2013.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

vi. Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

Amortization of intangible assets

Intangible assets are amortized on a straight-line basis over the period of 3 years.

vii. Impairment of property, plant and equipment and intangible assets

The company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) net selling price and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining net selling price, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used.



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

Impairment losses of continuing operations, including impairment on inventories, are recognized in the statement of profit and loss.

After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the company estimates the asset's or cash-generating unit's recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the statement of profit and loss.

viii. Investments

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost. However, provision for diminution in value is made to recognize a decline other than temporary in the value of the investments.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

ix. Income tax

Tax expense comprises current and deferred tax. Current income-tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India and tax laws prevailing in the respective tax jurisdictions where the company operates. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Deferred income taxes reflect the impact of timing differences between taxable income and accounting income originating during the current year and reversal of



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

timing differences for the earlier years. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted at the reporting date.

Deferred tax liabilities are recognized for all taxable timing differences. Deferred tax assets are recognized for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

The carrying amount of deferred tax assets are reviewed at each reporting date. The company writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available

Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets and deferred taxes relate to the same taxable entity and the same taxation authority.

x. Foreign currency translation

Foreign currency transactions and balances

a. Initial Recognition:

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

b. Conversion:

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date.

c. Exchange Differences:

All exchange differences arising are recognized as income or as expenses in the period in which they arise.

xi. Retirement and other employee benefits

a. Gratuity

All the employees are covered under Employee Gratuity Scheme which is a defined benefit plan and is determined on the basis of actuarial valuation at each year-end.



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

Separate actuarial valuation is carried out for each plan using the projected unit credit method. Actuarial gains and losses for defined benefit plans are recognized in full in the period in which they occur in the statement of profit and loss.

b. Provident fund

Retirement benefit in the form of provident fund is a defined contribution scheme. The company has no obligation, other than the contribution payable to the provident fund. The company recognizes contribution payable to the provident fund scheme as an expenditure, when an employee renders the related service.

c. Leave Entitlements

Leave entitlement benefit is recognized as an expense at the undiscounted amount in the statement of Profit and Loss for the financial year in which the related service is rendered. However, said expense is recognized for the period January to March each year based on last drawn salary. There is no carry forward of privilege leave and casual leave on calendar year basis.

d. Sick leave

The Company provides for sick leave covering eligible employees on the basis of actuarial valuation carried out by an independent valuer at the year-end. Actuarial gains and losses in respect of defined benefits are charged to the statement of profit & loss.

The Company accrues Sick leave at the rate of seven days per annum on calendar year basis and maximum of accumulation is restricted to Thirty days. This benefit is available only in the event of employee falling sick during the tenure of his service. No credit is allowed in respect of accumulated sick leave in the event of cessation of service due to any cause.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date. Where company has the unconditional legal and contractual right to defer the settlement for a period beyond 12 months, the same is presented as non-current liability.



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

xii. Provisions, contingent liability and contingent asset:

Provisions:

A provision is recognized when the company has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

Contingent liability

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

Contingent asset;

Contingent asset are neither recognized nor disclosed in the financial statement.

xiii. Cash and cash equivalent

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

xiv. Borrowing Costs

Borrowing cost includes interest and amortization of ancillary costs incurred in connection with the arrangement of borrowings.

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

xv. Operating lease

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease



Veeda Clinical Research Private Limited

Notes to the Standalone Financial Statements for the year ended March 31, 2019

payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

xvi. Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

xvii. Segment Reporting

The company is providing services of testing and contract research in the fields of clinical and analytical testing. Since the inherent nature of all these services are inter related and governed by the same set of risks and returns and operating in the same economic environment, the Company falls within a single business segment of clinical research services. The analysis of geographical segments is based on the geographical location of the customer.



3 Share Capital

| Particulars | As at March 31, 2019 | | As at March 31, 2018 | |
|--|----------------------|--------------------|----------------------|--------------------|
| | Number | Amount in Rs. | Number | Amount in Rs. |
| Authorised Share Capital | | | | |
| a. Equity Shares of Rs. 10 each | 600,000 | 6,000,000 | 600,000 | 6,000,000 |
| b. 0.0001% Cumulative Compulsory Convertible Participatory Preference Share of Class 'A' Rs. 10 each | 35,640,680 | 356,406,800 | 100,000 | 1,000,000 |
| c. 16% Cumulative Compulsory Convertible Participatory Preference Share of Class 'B' Rs. 3340 each | - | - | 51,020 | 170,406,800 |
| Total | 36,240,680 | 362,406,800 | 751,020 | 177,406,800 |

| Particulars | As at March 31, 2019 | | As at March 31, 2018 | |
|--|----------------------|--------------------|----------------------|--------------------|
| | Number | Amount in Rs. | Number | Amount in Rs. |
| Issued, Subscribed & Paid Up Share Capital | | | | |
| a. Equity Shares of Rs. 10 each | 587,163 | 5,871,630 | 547,775 | 5,477,750 |
| b. 0.0001% Cumulative Compulsory Convertible Participatory Preference Share of Class 'A' Rs. 10 each | 35,229,780 | 352,297,800 | - | - |
| c. 16% Cumulative Compulsory Convertible Participatory Preference Share of Class 'B' Rs. 3340 each | - | - | 51,018 | 170,400,120 |
| Total | 35,816,943 | 358,169,430 | 598,793 | 175,877,870 |

(a) Reconciliation of the shares outstanding at the beginning and at the end of the reporting year
Equity Share Capital

| Particulars | As at March 31, 2019 | | As at March 31, 2018 | |
|--|----------------------|------------------|----------------------|------------------|
| | Number | Amount in Rs. | Number | Amount in Rs. |
| Shares outstanding at the beginning of the year | 547,775 | 5,477,750 | 547,775 | 5,477,750 |
| Conversion of preference shares class-B into equity shares during the year | 39,388 | 393,880 | - | - |
| Shares outstanding at the end of the year | 587,163 | 5,871,630 | 547,775 | 5,477,750 |

Preference Share Capital - Compulsorily Convertible (CCPS) Class "A"

| Particulars | As at March 31, 2019 | | As at March 31, 2018 | |
|--|----------------------|--------------------|----------------------|---------------|
| | Number | Amount in Rs. | Number | Amount in Rs. |
| Shares outstanding at the beginning of the year | - | - | - | - |
| Shares Issued during the year - Bonus issue | 35,229,780 | 352,297,800 | - | - |
| Shares outstanding at the end of the year | 35,229,780 | 352,297,800 | - | - |

Preference Share Capital - Compulsorily Convertible (CCPS) Class "B"

| Particulars | As at March 31, 2019 | | As at March 31, 2018 | |
|--|----------------------|---------------|----------------------|--------------------|
| | Number | Amount in Rs. | Number | Amount in Rs. |
| Shares outstanding at the beginning of the year | 51,018 | 170,400,120 | 51,018 | 170,400,120 |
| Shares bought back during the year | 11,630 | 38,844,200 | - | - |
| Conversion of preference shares class-B into equity shares during the year | 39,388 | 131,555,920 | - | - |
| Shares outstanding at the end of the year | - | - | 51,018 | 170,400,120 |

(b) Terms / rights attached to equity shares.

In respect of Ordinary shares (whether fully paid or partly paid), voting rights shall be in the same proportion as the capital paid upon such ordinary share bears to the total paid up ordinary capital of the company.

The Dividend proposed by the board of Directors, if any, is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

In the event of liquidation, the shareholders of Ordinary shares are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholdings.

(c) Terms of conversion / redemption of CCPS - Class B.

- Dividend at 8.5% per annum of the issue price of such preference shares for the financial year ended March 31, 2009 on pro rata basis;
- Dividend at 12.5% per annum of the issue price of such preference shares for the financial year ended on March 31, 2010 ; and
- Dividend at 16% or maximum rate as permissible under law per annum (whichever is lower) of the issue price of such preference shares for the financial year ended March 31, 2011 and for each year thereafter.
- The Preference Share holders shall be entitled to convert Preference Shares at the option of share holders at anytime during the period commencing from the expiry of 1 year to 20 year from the allotment of preference shares. In case, the same option is not exercised by the preference share holders, it shall be compulsorily converted into equity shares automatically at the expiry of 20 years of the date of allotment.

v. Conditions for Dividend :

The preference share shall be entitled to dividend for the full financial year on pro rata basis for the year in which such shares are allotted. If no dividend is paid for any financial year then the same shall stand accumulated and shall be paid before making payment of dividend on equity shares for any financial year.



The preference shares shall carry right to participate in profits provided the dividend declared / paid on Equity shares exceeds the dividend amount of preference shares for the corresponding financial year.
On conversion, the dividend accumulated till the date of conversion shall be payable at the time of conversion.

- (d) Terms of conversion / redemption of CCPS - Class A:
- The CCPS A shall be entitled to 0.0001% participatory and cumulative dividend.
 - The CCPS A shall not be entitled to any voting rights.
 - The conversion of CCPS A in to equity shares shall be subject to the approval of the Board of Directors of the Company. The maximum number of equity shares into which the CCPS A can get converted is 93,946 equity shares.
 - The rights of preference shareholders shall be governed in accordance with the provisions of the Companies Act, 2013, including any statutory modification(s) and re-enactment(s), thereof, and the Memorandum and Articles of Association of the Company, as may be amended from time to time.
 - The conversion of CCPS A in to equity shares shall be subject to all rules, regulations prevailing / applicable at the time of such conversion and shall be subject to approvals / conditions of Central Government of India, Reserve Bank of India and such other statutory authority as may be applicable and prevailing at the time of conversion.

(e) Shares held by holding company

| Name of Shareholder | As at March 31, 2019 | | As at March 31, 2018 | |
|--|----------------------|---------------|----------------------|---------------|
| | Number | Amount in Rs. | Number | Amount in Rs. |
| Basil Private Limited | | | | |
| a. Equity Shares of Rs. 10 each | 406,194 | 4,061,940 | - | - |
| b. 0.0001% Cumulative Compulsory Convertible Participatory Preference Share of Class 'A' Rs. 10 each | - | - | - | - |
| c. 16% Cumulative Compulsory Convertible Participatory Preference Share of Class 'B' Rs. 3340 each | - | - | - | - |
| Bondway Investment Inc. | | | | |
| a. Equity Shares of Rs. 10 each | 159,708 | 1,597,080 | 349,900 | 3,499,000 |
| b. 0.0001% Cumulative Compulsory Convertible Participatory Preference Share of Class 'A' Rs. 10 each | 22,175,640 | 221,756,400 | - | - |
| c. 16% Cumulative Compulsory Convertible Participatory Preference Share of Class 'B' Rs. 3340 each | - | - | 25,509 | 85,200,060 |

- (f) Aggregate number of bonus shares issued and shares bought back during the period of five years immediately preceding the reporting date

| Particulars | For the year ended March 31, 2019 (Number) | For the year ended March 31, 2018 (Number) |
|--|--|--|
| Preference shares class "A" allotted as fully paid-up bonus shares | 35,229,780 | - |
| Preference shares class "B" bought back by the company | 11,630 | - |

- (g) Details of Shareholders holding more than 5% shares in the company

| Equity Share Capital | | | | |
|----------------------------------|----------------------|--------------|----------------------|--------------|
| Name of Shareholder | As at March 31, 2019 | | As at March 31, 2018 | |
| | Number | % of Holding | Number | % of Holding |
| Bondway Investment Inc. | 159,708 | 27.20 | 349,900 | 63.88 |
| Basil Private Limited | 406,194 | 69.18 | - | - |
| Arabelle Financial Services Ltd. | - | - | 197,775 | 36.11 |

Preference Share Capital Class - "A"

| Name of Shareholder | As at March 31, 2019 | | As at March 31, 2018 | |
|----------------------------------|----------------------|--------------|----------------------|--------------|
| | Number | % of Holding | Number | % of Holding |
| Bondway Investment Inc. | 22,175,640 | 62.95 | - | - |
| Arabelle Financial Services Ltd. | 13,048,140 | 37.04 | - | - |

Preference Share Capital Class - "B"

| Name of Shareholder | As at March 31, 2019 | | As at March 31, 2018 | |
|----------------------------------|----------------------|--------------|----------------------|--------------|
| | Number | % of Holding | Number | % of Holding |
| Bondway Investment Inc. | - | - | 25,509 | 50.00 |
| Arabelle Financial Services Ltd. | - | - | 25,509 | 50.00 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

4 Reserves and surplus

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| a. Securities premium account | | |
| Opening Balance | 641,179,464 | 641,179,464 |
| Less: Amount utilized towards buy-back of Preference shares class-B | 129,555,800 | - |
| Less: Amount transferred to capital redemption reserve upon buy-back of preference shares class-B | 38,844,200 | - |
| Less: Amount transferred to capital redemption reserve upon conversion of preference shares class-B | 131,555,920 | - |
| Add : Amount transferred on conversion of preference shares class-B | 131,162,040 | - |
| Less: utilized for issue of bonus shares | 352,297,800 | - |
| Closing balance | 120,087,784 | 641,179,464 |
| b. Capital redemption reserve | | |
| Opening balance | - | - |
| Add: Amount transferred to capital redemption reserve upon buy-back of preference shares class-B | 38,844,200 | - |
| Add: Amount transferred to capital redemption reserve upon conversion of preference shares class-B | 131,555,920 | - |
| Closing balance | 170,400,120 | - |
| c. Surplus/(deficit) in the statement of profit & loss | | |
| Opening balance | 32,900,575 | (276,208,806) |
| Add: Profit for the year | 526,206,557 | 309,109,380 |
| Less: Dividend paid to preference share holders | 259,351,316 | - |
| Less: Tax paid on distribution of dividend to preference share holders | 53,310,426 | - |
| Closing balance | 246,445,390 | 32,900,575 |
| Total reserves and surplus | 536,933,294 | 674,080,039 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

5 Long-term borrowings

(Amount in Rs.)

| Particulars | As at March 31, 2019 | | As at March 31, 2018 | |
|---------------------------------------|----------------------|---|----------------------|---|
| | Non-current | Current maturity (Refer note no. 10) | Non-current | Current maturity (Refer note no. 10) |
| Term Loans | | | | |
| From financial institutions (secured) | - | 54,912,156 | 99,952,635 | 55,329,415 |
| Total | - | 54,912,156 | 99,952,635 | 55,329,415 |

Details of terms and securities for the above Rupee Loan facilities are as follows:

1) Term Loan amounting Rs. 3,17,95,380 from GE Capital Service India ('GECSI') for purchase of various medical equipment. Outstanding balance for this facility is Rs. 1,08,55,280 (31 March 2018: Rs. 1,77,62,768). The borrowing carries interest @ 295 basis points above the effective State Bank of India based rate (Benchmark rate) payable on monthly rest. The effective interest rate is 12.00% (31 March 2018: 11.60%). The Term Loan is repayable in structured monthly instalment and repayment started from 26 April 2015. The Rupee Term Loan facilities are Secured against the first and exclusive charge on the equipment financed by GECSI and against the personal guarantee of Mr. Binoy Gardi and Mr. Apurva Shah. The loan has been repaid subsequent to yearend.

2) Term Loan amounting Rs. 5,00,00,000 from Tata Capital Financial Services Limited ('TATA') for purchase of equipment. Outstanding balance for this facility is Rs. Nil (31 March 2018: Rs. 1,23,23,512). The borrowing carries interest @ long term lending rate less 4.75% subject to minimum of 13% payable on monthly rest. The effective interest rate ranging between 13.50% to 14.25% (31 March 2018: 13.50%). The Term Loan is repayable in structured monthly instalment and repayment started from 15 February 2016. The Rupee Term Loan facilities are Secured against the first and exclusive charge on the equipment financed by TATA and against the personal guarantee of Mr. Binoy Gardi and Mr. Apurva Shah.

Term Loan amounting Rs. 10,00,00,000 from Tata Capital Financial Services Limited ('TATA') for purchase of equipment. Outstanding balance for this facility is Rs. 4,42,32,357 (31 March 2018: Rs. 6,93,69,208). The borrowing carries interest @ long term lending rate less 5.25% payable on monthly rest. The effective interest rate is 12.25% to 13.25% (31 March 2018: 12.25%). The Term Loan is repayable in structured monthly instalment and repayment started from 25 January 2017. The Rupee Term Loan facilities are Secured against the first and exclusive charge on the equipment financed by TATA and against the personal guarantee of Mr. Binoy Gardi and Mr. Apurva Shah. The loan has been repaid subsequent to yearend.

3) Term Loan amounting Rs. 2,67,00,000 from Hero FinCorp Limited for purchase of equipment. Outstanding balance for this facility is Rs. Nil (31 March 2018: Rs. 2,63,30,859). The borrowing carries floating interest ranging between 12.00% to 13.50% (31 March 2018: 12.00%). The Term Loan is repayable in structured monthly instalment and repayment started from 08 Feb 2018. The full loan has been prepaid on 13 March 2019. The Rupee Term Loan facilities are Secured against the first and exclusive charge on the equipment financed by Hero FinCorp and against the personal guarantee of Mr. Binoy Gardi and Mr. Apurva Shah.

Term Loan amounting Rs. 4,28,00,000 from Hero FinCorp Limited for purchase of equipment. Outstanding balance for this facility is Rs. Nil (31 March 2018: Rs. 3,01,09,560). The borrowing carries floating interest ranging between 13.50% to 15.00% (31 March 2018: 13.50%). The Term Loan is repayable in structured monthly instalment and repayment started from 08 Mar 2016. The full loan has been prepaid on 27 March 2019. The Rupee Term Loan facilities are Secured against the first and exclusive charge on the equipment financed by Hero FinCorp and against the personal guarantee of Mr. Binoy Gardi and Mr. Apurva Shah.



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

6 Other long-term liabilities

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|--------------------|-------------------------|-------------------------|
| Lease equalisation | 21,613,271 | 14,933,687 |
| Security deposits | 500,000 | 500,000 |
| Total | 22,113,271 | 15,433,687 |

7 Long-term provisions

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Provision for gratuity (Refer to Note No. 26.1 & Note No. 26.2) | 18,689,208 | 14,240,362 |
| Provision for leave benefits | 2,108,238 | 1,042,133 |
| Total | 20,797,446 | 15,282,495 |

8 Short term borrowings

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Loans repayable on demand - secured | | |
| Foreign currency demand loan (FCDL) from Bank | 48,842,890 | - |
| Total | 48,842,890 | - |

The Company has obtained Foreign Currency Demand Loan ('FCDL') facility of Rs. 20,00,00,000 from Axis Bank for working capital requirement of the Company. Outstanding balance for this facility is Rs. 4,88,42,890 (31 March 2018: Rs. Nil). The borrowing carries interest of 6 months libor + 2.50 bps payable on monthly rest. The effective interest rate is 5.185% (31 March 2018: Nil). The FCDL is repayable on demand.

The FCDL is secured:

(a) by way of hypothecation on entire current assets of the Company including stock and receivables, both present and future.

(b) by way of equitable mortgage / hypothecation of immovable / moveable fixed asset (plant and machinery / equipment etc.) other than those financed by other banks / financial institution.

(c) against TDR in the name of Company having value of Rs. 4,01,00,000.

(d) against the personal guarantee of Mr. Binoy Gardi and Mr. Apurva Shah.



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

9 Trade payable

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Total outstanding dues of micro enterprises and small enterprises (Refer to Note No. 34) | 17,209,552 | 22,680 |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 94,896,835 | 79,210,020 |
| Total | 112,106,387 | 79,232,700 |

10 Other current liabilities

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Current maturity of long-term borrowing (refer to note No. 5) | 54,912,156 | 55,329,415 |
| Statutory dues payable | 14,129,601 | 24,377,099 |
| Advance from customers | 71,867,320 | 80,524,269 |
| Creditors for capital goods | 5,707,887 | 2,728,740 |
| Current portion of lease equalisation (refer to note No. 6) | 568,933 | 4,729,035 |
| Provisions for expenses | 9,528,502 | 8,346,745 |
| Provisions for employee benefit expense | 51,008,440 | 34,308,355 |
| Interest accrued but not due on borrowings | 175,481 | 613,857 |
| Payable to customer | 18,417,897 | 24,422,433 |
| Others | 514,276 | 62,550 |
| Total | 226,830,493 | 235,442,498 |

11 Short term provisions

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Provision for gratuity (Refer to note No. 26.1 & Note No. 26.2) | 4,365,967 | 3,595,226 |
| Provision for leave benefits | 6,102,171 | 3,530,900 |
| Total | 10,468,138 | 7,126,126 |



12. Property, plant & equipment
FY 2018-19

| Particulars | GROSS BLOCK (at cost) | | | | DEPRECIATION | | | | NET BLOCK | |
|-------------------------------------|--------------------------------------|------------|-----------|--------------------------------------|--------------------------------------|--------------|-----------|--------------------------------------|----------------------|----------------------|
| | Opening balance as at April 01, 2018 | Addition | Deduction | Closing balance as at March 31, 2019 | Opening balance as at April 01, 2018 | For The Year | Deduction | Closing balance as at March 31, 2019 | As at March 31, 2019 | As at March 31, 2018 |
| TANGIBLE ASSETS | | | | | | | | | | |
| Leasehold improvements | 88,594,547 | 2,448,793 | - | 91,043,340 | 48,126,947 | 8,418,940 | - | 56,545,887 | 34,497,453 | 40,467,601 |
| Plant & machinery | 857,806,543 | 16,018,342 | - | 873,824,885 | 489,219,804 | 72,296,994 | - | 561,516,798 | 312,308,087 | 368,586,739 |
| Office equipment | 14,963,975 | 1,840,377 | - | 16,804,352 | 12,403,625 | 1,564,232 | - | 13,967,857 | 2,836,495 | 2,560,350 |
| Computers | 40,419,270 | 6,397,635 | 27,550 | 46,789,355 | 34,140,810 | 4,556,744 | 26,173 | 38,671,381 | 8,117,974 | 6,278,459 |
| Furniture & fixtures | 60,741,191 | 3,220,216 | - | 63,961,407 | 45,614,262 | 4,598,947 | - | 50,213,209 | 13,748,198 | 15,126,929 |
| Vehicles | 9,477,854 | 1,197,794 | - | 10,675,648 | 7,173,779 | 671,101 | - | 7,844,880 | 2,830,767 | 2,304,074 |
| Total (A) | 1,072,003,380 | 31,123,157 | 27,550 | 1,103,098,987 | 636,679,227 | 92,106,957 | 26,173 | 728,760,012 | 374,338,975 | 435,324,152 |
| INTANGIBLE ASSETS | | | | | | | | | | |
| Computer software | 14,455,322 | 1,561,241 | - | 16,016,563 | 10,541,522 | 2,282,700 | - | 12,824,222 | 3,192,341 | 3,913,800 |
| Total (B) | 14,455,322 | 1,561,241 | - | 16,016,563 | 10,541,522 | 2,282,700 | - | 12,824,222 | 3,192,341 | 3,913,800 |
| TOTAL (A)+(B) | 1,086,458,702 | 32,684,398 | 27,550 | 1,119,115,550 | 647,220,749 | 94,389,657 | 26,173 | 741,584,234 | 377,531,315 | 439,237,952 |
| Previous year | 996,824,269 | 91,164,118 | 1,529,684 | 1,086,458,703 | 542,533,237 | 105,818,970 | 1,131,457 | 647,220,750 | 439,237,953 | 454,291,033 |
| Capital work in progress | 3,867,658 | 79,167,060 | 8,932,989 | 74,101,729 | - | - | - | - | 74,101,729 | 3,867,658 |
| Intangible assets under development | 2,040,125 | 1,215,075 | - | 3,255,200 | - | - | - | - | 3,255,200 | 2,040,125 |

FY 2017-18

| Particulars | GROSS BLOCK (at cost) | | | | DEPRECIATION | | | | NET BLOCK | |
|-------------------------------------|--------------------------------------|-------------|------------|--------------|--------------------------------------|--------------------------------------|--------------|-----------|--------------|--------------------------------------|
| | Opening balance as at April 01, 2017 | Addition | Deduction | Adjustments | Closing balance as at March 31, 2018 | Opening balance as at April 01, 2017 | For The Year | Deduction | Adjustments | Closing balance as at March 31, 2018 |
| TANGIBLE ASSETS | | | | | | | | | | |
| Leasehold improvements | 49,715,305 | 2,417,085 | - | 36,462,157 | 88,594,547 | 20,882,465 | 8,632,875 | - | 18,611,607 | 48,126,947 |
| Plant & machinery | 819,908,609 | 75,392,774 | 1,239,918 | (36,254,872) | 857,806,543 | 425,562,893 | 83,124,697 | 856,179 | (18,611,607) | 489,219,804 |
| Office equipment | 13,665,408 | 1,298,567 | - | - | 14,963,975 | 10,982,463 | 1,421,162 | - | - | 12,403,625 |
| Computers | 34,659,243 | 5,760,027 | - | - | 40,419,270 | 30,217,290 | 3,923,520 | - | - | 34,140,810 |
| Furniture & fixtures | 58,769,526 | 2,178,950 | - | (207,285) | 60,741,191 | 39,911,925 | 5,702,337 | - | - | 45,614,262 |
| Vehicles | 9,184,892 | 582,728 | 289,766 | - | 9,477,854 | 6,518,916 | 930,141 | 275,278 | - | 7,173,779 |
| Total (A) | 985,902,983 | 87,630,081 | 1,529,684 | - | 1,072,003,380 | 534,075,952 | 103,734,732 | 1,131,457 | - | 636,679,227 |
| INTANGIBLE ASSETS | | | | | | | | | | |
| Computer software | 10,921,285 | 3,534,037 | - | - | 14,455,322 | 8,457,284 | 2,084,238 | - | - | 10,541,522 |
| Total (B) | 10,921,285 | 3,534,037 | - | - | 14,455,322 | 8,457,284 | 2,084,238 | - | - | 10,541,522 |
| TOTAL (A)+(B) | 996,824,268 | 91,164,118 | 1,529,684 | - | 1,086,458,702 | 542,533,236 | 105,818,970 | 1,131,457 | - | 647,220,749 |
| Previous year | 852,664,365 | 144,189,287 | 29,383 | - | 996,824,269 | 429,974,304 | 112,563,597 | 4,665 | - | 542,533,237 |
| Capital work in progress | 1,924,189 | 14,952,209 | 13,008,740 | - | 3,867,658 | - | - | - | - | - |
| Intangible assets under development | 1,179,000 | 861,125 | - | - | 2,040,125 | - | - | - | - | - |

(Amount in Rs.)

Note: In FY 2017-18, The adjustment amount disclosed under Plant & Machinery, Furniture & Fixtures and Leasehold Improvement pertain to fixed installations at leasehold improvement. The amortization on the said assets has been computed as in case of other leasehold improvements. During the year ended March 31, 2018, the said assets have been reclassified to Leasehold Improvement.



Veeda Clinical Research Private Limited
Notes to Standalone Financial Statements for the year ended March 31, 2019

13 Non-current investments

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Non-trade investments (valued at cost) | | |
| Investments in equity shares of subsidiary (unquoted) | | |
| Nil (March 31, 2018 : 2) Equity shares of Veeda Clinical Research GmbH, Germany, fully paid | - | 1,429,633 |
| Total | - | 1,429,633 |

14 Deferred tax assets

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Difference between depreciable assets as per books of accounts and written down value for tax purpose | 25,820,381 | 25,385,650 |
| Employee benefits / expenses allowable on payment basis | 15,563,996 | 14,570,359 |
| Effect of adjustment under ICDS | 212,404 | 2,296,368 |
| Effect of provision for doubtful debt and diminution in value of investments | 3,007,142 | 3,347,762 |
| Deferred tax assets - total | 44,603,923 | 45,600,139 |

15 Long term loans and advances

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|--|-------------------------|-------------------------|
| Security deposits | | |
| Unsecured, considered good | 25,481,517 | 26,609,033 |
| Other loans and advances | | |
| Unsecured, considered good | | |
| Advance income tax (Net of provision for | 76,679,407 | 77,392,640 |
| Cenvat credit receivable | 20,963 | 20,965 |
| Balance with government authorities | 2,118,312 | 148,055,420 |
| Total | 104,300,199 | 252,078,058 |

16 Other non-current assets

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Prepaid expenses | - | 182,299 |
| Bank deposits with remaining maturity for more than 12 months * | 4,032,275 | 4,114,179 |
| Total | 4,032,275 | 4,296,478 |

* Bank Deposits amounting to Rs. 4,032,275 (March 31, 2018: Rs. 4,114,179) are given as security against bank guarantee.



17 Current investments

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Valued at lower of cost and fair value (Non-trade) | | |
| Investment in mutual funds | | |
| 36,121 Units (March 31, 2018: 36,121 Units) of ICICI Prudential Banking & Financial Services Fund (Direct Growth) | 2,250,000 | 2,175,951 |
| 1,15,169 Units (March 31, 2018: 1,15,169 Units) of IDFC Infrastructure Fund (Direct Growth) | 1,907,204 | 2,190,855 |
| Nil (March 31, 2018: 7,040 Units) of UTI Liquid Cash Plan-Institutional (Direct Growth) | - | 20,031,234 |
| 19,617 Units (March 31, 2018: 19,617 Units) of UTI Pharma & Healthcare Fund (Direct Growth) | 1,787,588 | 1,688,981 |
| 1,13,422 Units (March 31, 2018: Nil) of Aditya Birla Sunlife Banking & Financial Services Fund | 3,000,000 | - |
| 75,339 Units (March 31, 2018: Nil) of ICICI Prudential Focused Bluechip Equity Fund | 3,000,000 | - |
| 66,349 Units (March 31, 2018: Nil) of IDFC Classic Equity Fund | 3,000,000 | - |
| 1,72,812 Units (March 31, 2018: Nil) of L & T Infrastructure Fund | 2,770,161 | - |
| Total | 17,714,953 | 26,087,021 |

17.1 Details of quoted investments

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|--------------------------------------|-------------------------|-------------------------|
| Total amount of quoted investments | 18,300,000 | 26,300,000 |
| Market value of quoted investments | 18,527,737 | 26,087,021 |
| Total amount of unquoted investments | - | - |

18 Inventories

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|--|-------------------------|-------------------------|
| Valued at lower of cost and net realizable value | | |
| Consumables | 47,323,626 | 49,786,042 |
| Total | 47,323,626 | 49,786,042 |



Veeda Clinical Research Private Limited
Notes to Standalone Financial Statements for the year ended March 31, 2019

19 Trade receivables

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|--|-------------------------|-------------------------|
| Outstanding for a period exceeding six months from the date they are due for payment | | |
| Unsecured, considered good | 31,026,228 | 23,701,165 |
| Considered doubtful | 8,089,990 | 9,459,837 |
| Less: Provision for Doubtful receivables | (8,089,990) | (9,459,837) |
| Total | 31,026,228 | 23,701,165 |
| Other receivables | | |
| Unsecured, considered good | 371,084,166 | 423,374,862 |
| Total | 402,110,394 | 447,076,027 |
| Net unearned revenue | 34,159,008 | (71,434,210) |
| Total | 436,269,402 | 375,641,817 |

20 Cash and bank balances

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Cash and cash equivalents | | |
| Balances with Banks: | | |
| -On current accounts and cash credit accounts | 108,630,149 | 65,177,694 |
| -Deposits with original maturity of less than three months | 65,000,000 | - |
| Cash on hand | 2,927,759 | 1,147,273 |
| Other bank balances | | |
| - Deposits with remaining maturity of less than 12 months @ | 24,600,000 | 15,000,000 |
| Total | 201,157,908 | 81,324,967 |

@ Bank Deposits amounting to Rs. 24,600,000 (March 31, 2018: Rs. 15,000,000) are given as collateral security against cash credit limits.

21 Short term loans and advances

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|----------------------------|-------------------------|-------------------------|
| Security deposits | | |
| Unsecured, considered good | 6,884,161 | - |
| Other loans and advances | | |
| Unsecured, considered good | - | 511,331 |
| Prepaid expenses | 9,270,408 | 7,765,846 |
| Advance to creditors | 7,034,736 | 42,111 |
| Other receivable | 168,485 | 613,126 |
| Inter corporate loans | - | 2,966,686 |
| Total | 23,357,790 | 11,899,100 |

22 Other current assets
(Unsecured considered good)

(Amount in Rs.)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|---|-------------------------|-------------------------|
| Export incentive receivable | - | 4,633,526 |
| Interest accrued on fixed deposits | 2,048,550 | 1,164,613 |
| Interest accrued but not due on security deposits | 302,919 | 340,920 |
| Advance for investments | - | 3,000,000 |
| Others | 261,559 | - |
| Total | 2,613,028 | 9,139,059 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

23 Revenue from operations

(Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---|------------------------------|------------------------------|
| Revenue from operations | | |
| Sale of services | 2,098,233,172 | 1,824,741,151 |
| Other operating income | | |
| Export incentives income (Refer to Note No. 39) | 86,209,845 | (202,500) |
| Total | 2,184,443,017 | 1,824,538,651 |

24 Other income

(Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---|------------------------------|------------------------------|
| Interest income on | | |
| -Bank deposits | 2,462,399 | 2,617,215 |
| -Others | 2,771,594 | 1,124,712 |
| Gain (net of loss) on sale of asset | 2,723 | - |
| Net gain on foreign currency transactions | 5,099,319 | 4,032,811 |
| Gain on sale of mutual funds | 6,607,129 | - |
| Gain on sale of long term investments | 906,126 | - |
| Credit balances written back | 35,526,035 | - |
| Total | 53,375,325 | 7,774,738 |



25 Cost of material consumed

(Amount In Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|-------------------------------------|------------------------------|------------------------------|
| Opening stock of consumables | 49,786,042 | 42,330,213 |
| Purchase | 140,872,955 | 162,141,808 |
| Less : Closing stock of consumables | (47,323,626) | (49,786,042) |
| Total | 143,335,371 | 154,685,979 |

26 Employee benefit expenses

(Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---|------------------------------|------------------------------|
| Salary, bonus and allowances | 436,135,443 | 331,915,139 |
| Contributions to provident and other funds (refer note below) | 20,621,021 | 17,356,058 |
| Staff welfare expenses | 5,082,029 | 5,570,416 |
| Total | 461,838,493 | 354,841,613 |

26.1 A. Defined contribution plans : Provident fund and employee state insurance

The company makes contribution towards employees' provident fund and employees' state insurance plan scheme. Under the rules of these schemes, the Company is required to contribute a specified percentage of payroll costs. During the year, company recognized Rs. 14,570,302 (31st March, 2018: Rs. 13,145,971) as expense towards contributions to these plans.

B. Defined benefit plans - Gratuity

The Company provides for gratuity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement / termination is the employees last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service. The gratuity plan is a non funded plan.

26.2 Actuarial assumptions (gratuity)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|--|--|--|
| Discount rate | 7.20% | 7.35% |
| Expected rate of return on plan assets | 7.20% | 7.35% |
| Salary escalation rate | 12.00% p.a for next 3 years & 7.00% p.a thereafter | 12.00% p.a for next 4 years & 7.00% p.a thereafter |
| Mortality rate | Indian Assured Lives Mortality (2006-08) Table | Indian Assured Lives Mortality (2006-08) Table |

26.3 Actuarial assumptions (gratuity)

(Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---|------------------------------|------------------------------|
| (i) Change in present value of obligation | | |
| Present value of obligation at the beginning of the year | 17,943,076 | 14,404,079 |
| Interest cost | 1,225,240 | 907,670 |
| Current service cost | 3,595,226 | 3,282,878 |
| Benefit paid | (806,490) | (697,373) |
| Actuarial (gain)/loss in obligations | 1,164,569 | (906,915) |
| Past service cost | - | 952,737 |
| Present value of obligation at year end | 23,121,621 | 17,943,076 |
| (ii) Change in the fair value of plan assets | | |
| Fair value of planned assets at the beginning of the year | 62,393 | 59,642 |
| Expected return on the plan assets | 43,134 | 43,866 |
| Contributions by the employer | - | - |
| Benefits paid | - | - |
| Adjustment to opening | - | - |
| Actuarial (gain)/loss on plan assets | (39,080) | (41,115) |
| Fair value of planned assets at year end | 66,447 | 62,393 |
| (iii) Percentage of each category of plan assets to total fair value of plan assets as at March 31, 2019 and March 31, 2018 respectively. | | |
| Administered by Max New York Life Insurance Company Ltd. | Nil | Nil |
| (iv) Expenses recognized in statement of profit & loss | | |
| Current service cost | 3,595,226 | 3,282,878 |
| Interest on obligation | 1,225,240 | 907,670 |
| Expected returns on plan assets | (43,134) | (43,866) |
| Net actuarial (gain)/loss recognized during the year | 1,203,649 | (865,800) |
| Recognized past service cost vested | 45,096 | 907,641 |
| Total expenses recognized in Statement of Profit & Loss. | 6,026,077 | 4,188,523 |
| (v) Reconciliation or present Value of the obligation and the Fair value of the plan Assets | | |
| Present value of the obligation at year end | 23,121,621 | 17,943,076 |
| Fair value of plan assets at year end | 66,447 | 62,393 |
| Unrecognized past service cost | - | 45,096 |
| Net Liability recognized in the balance sheet | 23,055,174 | 17,835,587 |



| Sr. No. | Particulars | Gratuity | | | |
|---------|--|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| | | For the year ended March 31, 2019 | For the year ended March 31, 2018 | For the year ended March 31, 2017 | For the year ended March 31, 2016 |
| (i) | Present value of obligation at year end | 23,121,621 | 17,943,076 | 14,404,079 | 9,118,951 |
| (ii) | Fair value of planned assets at year end | 66,447 | 62,393 | 59,642 | 44,824 |
| (iii) | Surplus (deficit) in the plan | (23,055,174) | (17,880,683) | (14,344,437) | (9,074,127) |
| (iv) | Experience adjustments on plan liabilities | 889,922 | (395,644) | 1,615,085 | 852,746 |
| (v) | Actuarial loss/(gain) due to change in assumptions | 200,913 | (511,271) | 2,471,163 | (115,146) |
| (vi) | Actuarial loss/(gain) due to change in demographic assumptions | 73,734 | - | - | - |
| (vii) | Experience adjustments on plan assets | 39,080 | 41,115 | (14,818) | 62,009 |
| (viii) | Net actuarial loss/(gain) for the year | 1,203,649 | (865,800) | 4,071,430 | 799,609 |

27 Finance costs (Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---------------------------------------|---------------------------|---------------------------|
| Interest expense on | | |
| -Borrowings | 16,310,324 | 22,931,824 |
| -Delayed payment of income tax | 4,414,510 | 271,530 |
| -Others | 455,723 | - |
| Bank charges and other borrowing cost | 2,668,828 | 3,758,142 |
| Total | 23,849,385 | 26,961,496 |

28 Other expenses (Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|--|---------------------------|---------------------------|
| Clinical analytical research expenses | 343,834,205 | 334,803,081 |
| Marketing & business promotion expenses | 28,262,169 | 15,613,877 |
| Rent | 63,368,685 | 64,874,941 |
| Water & power charges | 57,275,797 | 49,106,018 |
| Legal & professional charges | 31,657,648 | 25,165,731 |
| House keeping & security expenses | 65,893,335 | 68,180,191 |
| Professional charges of phlebotomists, nurses & doctors | 20,814,717 | 18,355,655 |
| Bio analytical research expenses | 17,863,558 | 20,665,359 |
| Insurance expenses | 6,409,599 | 5,639,420 |
| Conveyance & petrol expenses | 1,896,240 | 1,855,262 |
| Telephone expenses | 3,278,290 | 3,073,706 |
| Repairs & maintenance | | |
| -Buildings | 3,487,780 | 3,315,831 |
| -Plant & machinery & others | 48,988,790 | 47,142,116 |
| Rates & taxes | 11,813,602 | 9,790,887 |
| Payments to the auditor (Refer note below) | 1,250,000 | 850,000 |
| Expenditure towards CSR activities (Refer to Note No. 37) | 2,184,000 | 7,131,000 |
| Net effect to the carrying amount of investment in mutual fund units | 372,067 | 212,979 |
| Provision for doubtful debts | - | 9,459,837 |
| Miscellaneous expenses | 47,552,181 | 27,075,968 |
| Total | 756,202,663 | 712,311,859 |

28.1 Payments to the auditor (Excluding tax and out of pocket expenses) (Amount in Rs.)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|--------------|---------------------------|---------------------------|
| Audit fees | 1,250,000 | 850,000 |
| Total | 1,250,000 | 850,000 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

29. Contingent Liabilities & Capital Commitments not provided for.

| (Amount in Rupees) | | |
|---|----------------|----------------|
| Particulars | March 31, 2019 | March 31, 2018 |
| Claims against the company not acknowledged as debts: | | |
| Income tax * | 107,454,297 | 40,803,925 |
| Service tax ** | 161,502,063 | 161,502,063 |
| Customs # | 4,751,609 | 4,751,609 |

*Income tax demand comprise demand from the Indian tax authorities for payment of additional tax of Rs 107,454,297 (March 31, 2018: Rs 40,803,925), upon completion of their tax review for the assessment year 2007-08 to 2014-15. The tax demands are mainly on account of disallowances relating to transfer pricing matters, expenditure to earn exempt income, depreciation on software, interest charged on loan advanced, capital expenditure charged to revenue, etc. claimed by the company under the Income tax Act. The matter is pending before various authorities. The said demand amounts have been already adjusted against refund of various years by Income Tax department and hence net demand is Nil in respect of such period.

**Service tax demand comprise demand from the Service tax authorities for payment of additional tax of Rs 161,502,063 (March 31, 2018: Rs 161,502,063), upon completion of their tax review for the financial year 2008-09 to 2015-16. The tax demands are on account denial of export of service under Rule 4 of place of provision of Services Rules, 2012, reversal of CENVAT credit under Rule 6(3) and 6(5), disallowance of input tax credit etc. The matter is pending before various authorities.

#Custom duty demand comprise demand from CBEC for payment of additional tax of Rs 4,751,609 (March 31, 2018: Rs 4,751,609), upon completion of their tax review for the financial year 2011-12 to 2016-17. The demand is on account denial of custom duty exemption benefit claimed under the Notification 12/2012 dated 17 March 2012. The matter is pending before commissioner.

The company is contesting the demands and the management, including its tax advisors, believe that its position will likely be upheld in the appellate process. No tax expense has been accrued in the financial statements for the tax demand raised. The management believes that the ultimate outcome of this proceeding will not have a material adverse effect on the company's financial position and results of operations.

Other claims not acknowledged as debt

Claim by a party arising out of a commercial contract: Rs. 101.89 crore (March 31, 2018 : Rs. 101.89 crore). The company has not acknowledged this claim. As advised by the external legal counsel, the claim is not legally tenable. Moreover, the company is adequately insured and the matter is intimated to Insurance Company as well. The company has filed detailed response to the claim lodged. The matter is pending at Commercial Court, Ahmedabad. In view of these the company does not foresee any losses on this count and accordingly no provision is made in books of accounts.

There are numerous interpretative issues relating to the Supreme Court (SC) judgement on Provident Fund dated 28th February, 2019. The company believes that the impact will not be material for the year ending March 31, 2019.



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

Undeclared accrued Preference share dividend

Undeclared accrued preference share dividend on cumulative compulsorily convertible participatory preference shares (Class A preference shares) is Rs. 151 (excluding Dividend Distribution Tax) as at March 31, 2019. (March 31, 2018: Nil).

Undeclared accrued preference share dividend on cumulative compulsorily convertible participatory preference shares (Class B preference Shares) is Nil as at March 31, 2019. (March 31, 2018: Rs. 245,681,959).

Capital commitments

At March 31, 2019, the company has commitments of Rs. 280.58 Lakhs (March 31, 2018: Rs. 43.67 Lakhs) relating to contracts with suppliers and contractors for the acquisition of plant and machinery, equipment and various civil contracts of capital nature, net of advances.

30. The following reflect the profit and share data used in the basic and diluted EPS computation.

(Amount in Rupees)

| Particulars | | Year ended on March 31, 2019 | Year ended on March 31, 2018 |
|---|---|------------------------------------|------------------------------------|
| Profit After Tax for the year | | 526,206,556 | 309,109,379 |
| Less: Preference dividend including DDT for the year | | 16,479,315 | 32,868,218 |
| Profit attributable to Equity Shareholders | A | 509,727,241 | 276,241,161 |
| Total number of equity shares at the end of the year | B | 587,163 | 547,775 |
| Nominal value of Equity Shares (Rs.) | | 10 | 10 |
| Weighted average number of equity shares | | | |
| For basic EPS | | 564,609 | 547,775 |
| For diluted EPS | | 658,555 | 692,739 |
| Basic earnings per share | | 902.80 | 504.30 |
| Diluted earnings per share | | 799.03 | 446.21 |
| Weighted average number of equity shares for basic EPS | | 564,609 | 547,775 |
| Effect of dilution: Issue of Pref. shares class-A as Bonus | | 93,946 | 144,964 |
| Weighted average number of equity shares adjusted for the effect of dilution | | 658,555 | 692,739 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

31. Unhedged foreign currency exposures.

Particulars of unhedged foreign currency as at reporting date:

Account Receivable

| Currency type | Amount in Foreign currency | Amount in Foreign currency | Equivalent amount in Indian Currency | Equivalent amount in Indian Currency |
|------------------------|----------------------------|----------------------------|--------------------------------------|--------------------------------------|
| | As at March 31, 2019 | As at March 31, 2018 | As at March 31, 2019 | As at March 31, 2018 |
| US Dollar | 3,103,853 | 2,827,896 | 214,697,561 | 183,937,984 |
| Euro | 831,831 | 730,348 | 64,635,288 | 58,882,112 |
| British pound sterling | 55,893 | 92,069 | 5,056,963 | 8,496,594 |
| Chinese Yuan Renminbi | - | 2,538 | Nil | 26,243 |
| Total | | | 284,389,812 | 251,342,933 |

Account Payable

(Amount in Rupees)

| Currency type | Amount in Foreign currency | Amount in Foreign currency | Equivalent amount in Indian Currency | Equivalent amount in Indian Currency |
|------------------------|----------------------------|----------------------------|--------------------------------------|--------------------------------------|
| | As at March 31, 2019 | As at March 31, 2018 | As at March 31, 2019 | As at March 31, 2018 |
| US Dollar | 987,968 | 430,681 | 68,339,019 | 28,013,267 |
| British pound sterling | 58,500 | 58,500 | 5,292,823 | 5,398,649 |
| Total | | | 73,631,842 | 33,411,916 |

32. The company has entered into operating leases for office premises. The leases have an average life of between 3 and 9 years with renewal option included in contract. Renewals are at the option of the lessee. Lease payment recognized in the statement of profit and loss for the year amounts to Rs. 62,040,696 (March 31, 2018: Rs. 63,082,613).

Future minimum rental payable under non-cancellable operating lease are as follows:

(Amount in Rupees)

| Particulars | March 31, 2019 | March 31, 2018 |
|---|--------------------|--------------------|
| Less than one year | 54,427,954 | 59,335,053 |
| More than one year but less than five years | 194,530,771 | 218,562,104 |
| More than five years | 29,920,178 | 79,075,697 |
| Total | 278,878,903 | 356,972,854 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

33. Related Party Transactions.

a. Holding Company.

| Sr. No. | Particulars |
|---------|--|
| 1 | Bondway Investment Inc. (Till Nov 21, 2018) |
| 2 | Basil Private Limited (W.e.f. Nov 21, 2018) |

b. Subsidiary.

| Sr. No. | Particulars |
|---------|---|
| 1 | Veeda Clinical Research GmbH (Till July 20, 2018) |

c. Enterprises having significant influence.

| Sr. No. | Particulars |
|---------|--|
| 1 | Arabelle Financial Services Ltd. (Till Nov 21, 2018) |

d. Key management personnel.

| Sr. No. | Particulars |
|---------|--|
| 1 | Mr. Apurva Shah (Director) |
| 2 | Mr. Binoy Gardi (Director) |
| 3 | Mr. Ajay Tandon (Nominee Director) (W.e.f. Nov 21, 2018) |
| 4 | Mr. Saurabh Mehta (Nominee Director) (W.e.f. Nov 21, 2018) |
| 5 | Mr. Vinayak Shenvi (Alternate Director) (W.e.f. Nov 21, 2018) |
| 6 | Mr. Vivek Chhachhi (Nominee Director) (W.e.f. Nov 21, 2018) |
| 7 | Ms. Aparajita Jethy Ahuja (Nominee Director) (W.e.f. Nov 29, 2018) |
| 8 | Mr. Nirmal Bhatia (Company Secretary) (W.e.f. Oct 26, 2018) |

e. Relatives of key management personnel.

| Sr. No. | Particulars |
|---------|------------------|
| 1 | Ms. Sujata Gardi |
| 2 | Ms. Sonali Shah |

f. Enterprise in which key management personnel has significant control.

| Sr. No. | Particulars |
|---------|------------------------|
| 1 | Dura Paper Corporation |
| 2 | Jiwa Foods Pvt. Ltd. |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

- g. The following table provides the total amount of transactions that have been entered into with related parties for the relevant financial year.

| (Amount in Rupees) | | |
|--|---------------------------|---------------------------|
| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
| Holding Company | | |
| Dividend Paid to Preference Share Holders | | |
| Bondway Investment Inc. | 129,675,658 | - |
| Buy-back of preference shares class-B | | |
| Bondway Investment Inc. | 71,960,625 | - |
| Issue of Preference shares class-A as fully paid-up Bonus shares | | |
| Bondway Investment Inc. | 221,756,400 | |
| Subsidiary Company | | |
| Veeda Clinical Research GmbH, Germany | | |
| Services provided to Veeda GmbH (Sales Invoice raised - Net) | - | 542,569 |
| Enterprise having significant influence | | |
| Dividend Paid to Preference Share Holders | | |
| Arabelle Financial Services Ltd. | 129,675,658 | - |
| Buy-back of preference shares class-B | | |
| Arabelle Financial Services Ltd. | 71,960,625 | |
| Issue of Preference shares class-A as fully paid-up Bonus shares | | |
| Arabelle Financial Services Ltd. | 130,481,400 | |
| Key Management Personnel | | |
| Remuneration / Fees (Including perquisites) | | |
| 1. Mr. Apurva Shah | 8,300,556 | 3,144,596 |
| 2. Mr. Binoy Gardi | 17,490,222 | 1,759,410 |
| Salary (Including perquisites) | | |
| 1. Mr. Nirmal Bhatia | 4,384,206 | - |
| Rent - Expense | | |
| 1. Mr. Apurva Shah | 600,000 | 600,000 |
| 2. Mr. Binoy Gardi | 150,000 | 300,000 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

| | | |
|--|------------|-----------|
| Reimbursement of Expenses | | |
| 1. Mr. Apurva Shah | 2,178,802 | 712,672 |
| 2. Mr. Binoy Gardi | 19,030 | 44,466 |
| 3. Mr. Nirmal Bhatia | 104,196 | |
| Sale of Investment in Veeda Clinical Research GmbH, Germany | | |
| 1. Mr. Apurva Shah | 93,430 | - |
| 2. Mr. Binoy Gardi | 2,242,329 | - |
| Relatives of Key Managerial Personnel | | |
| Salary (Including perquisites) | | |
| 1. Ms. Sujata Gardi | 17,910,831 | 7,589,010 |
| 2. Ms. Sonali Shah | - | 639,596 |
| Enterprise in which key management personnel has Significant Control | | |
| Vehicle Hire Charges | | |
| Dura Paper Corporation | 693,000 | 1,369,500 |
| Sale of Asset | | |
| Jiwa Foods Pvt. Ltd. | - | 200,000 |

h. The Outstanding balances as at the end of year.

(Amount in Rupees)

| Particulars | As at March 31, 2019 | As at March 31, 2018 |
|--|----------------------|----------------------|
| Subsidiary - Veeda Clinical Research GmbH, Germany | | |
| Investment in Equity shares | - | 1,429,633 |
| Key Management Personnel | | |
| Remuneration / fees : | | |
| 1. Mr. Apurva Shah | 8,300,556 | 277,891 |
| Salary | | |
| 1. Mr. Nirmal Bhatia | 632,341 | - |
| Reimbursement of Expenses | | |
| 1. Apurva Shah | 513,193 | 47,731 |
| 2. Binoy Gardi | 19,030 | - |
| Relatives of Key Managerial Personnel | | |
| Salary | | |
| 1. Ms. Sonali Shah | - | 70,119 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

i. Related party as identified by the management and relied upon by the auditors.

Note: Indian rupee loans amounting to Rs. 54,912,156 and FCDL amounting to Rs. 48,842,890 from banks & financial institutions is guaranteed by the personal guarantee of Mr. Binoy Gardi and Mr. Apurva Shah. Indian rupee loans amounting to Rs. 54,912,156 from financial institutions have been repaid subsequent to yearend.

34. Details of dues to Micro, Small and Medium Enterprises as defined under the MSMED Act, 2006.

| Particulars | (Amount in Rupees) | |
|--|------------------------------|------------------------------|
| | Year ended March 31, 2019 | Year ended March 31, 2018 |
| a) Principal amount due to suppliers under MSMED Act, 2006 | 7,270,243 | 5,385,387 |
| b) Interest accrued, due to suppliers under MSMED Act on the above amount, and unpaid | 138,460 | - |
| c) Payment made to suppliers (other than interest) beyond the appointed day during the year | 19,703,283 | 18,477,868 |
| d) Interest paid to suppliers under MSMED Act (Section 16) | - | - |
| e) Interest due and payable towards suppliers under MSMED Act for payments already made | 317,263 | - |
| f) Interest accrued and remaining unpaid at the end of the year to suppliers under MSMED Act (including interest mentioned in (e) above) | 455,723 | - |

The above information is given to the extent available with the Company and relied upon by the auditor.

35. a. Imported and Indigenous consumables consumed.

| Value of Consumption of Imported and Indigenous Consumables and percentage thereof to the total Purchase: | Year ended March 31, 2019 | | Year ended March 31, 2018 | |
|---|---------------------------|---------------|---------------------------|---------------|
| | Value in Rs. | % | Value in Rs. | % |
| | | | | |
| Imported | 4,069 | 0.01 | 9,430,723 | 6.10 |
| Indigenous | 143,335,399 | 99.99 | 145,255,256 | 93.90 |
| Total | 143,339,468 | 100.00 | 154,685,979 | 100.00 |

b. CIF value of imports.

| Sr. No. | Particulars | (Amount in Rupees) | |
|---------|------------------------|------------------------------|------------------------------|
| | | Year ended March 31, 2019 | Year ended March 31, 2018 |
| i) | Capital Goods | 4,821,323 | 54,705,917 |
| ii) | Spares and Consumables | 5,247,819 | 19,832,266 |



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

c. Expenditure in Foreign Currency.

(Amount in Rupees)

| Sr. No. | Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---------|---|---------------------------|---------------------------|
| 1 | Marketing & business promotion expenses | 3,993,507 | 2,144,082 |
| 2 | Other expenses | 250,115 | 503,995 |
| 3 | Legal & professional charges | 286,789 | 937,206 |
| 4 | Telephone & internet expenses | 20,377 | 20,311 |
| 5 | Conveyance & petrol expenses | 67,563 | 109,325 |
| 6 | Basic salary | 51,522,464 | 15,789,110 |
| 7 | Clinical analytical research expenses | 619,914 | - |
| 8 | Telephone & internet expenses | 48,914 | - |

d. Earnings in Foreign Currency.

(Amount in Rupees)

| Particulars | Year ended March 31, 2019 | Year ended March 31, 2018 |
|---|---------------------------|---------------------------|
| Export Income from testing & other services | 1,249,502,353 | 994,805,212 |

36. Segment Reporting

Business Segment:

The company is engaged in the business of Clinical Research for various Pharmaceuticals Companies. Since the company's business falls within a single business segment of Clinical Research, no further financial information for business segment is given under Accounting Standard 17 "Segment Reporting".

Geographical Segment:

The company's secondary segments are the geographic distribution of activities. Revenue and carrying amount of segment Assets are specified by location of customers while the other geographic information is specified by location of the assets. The following tables present Revenue, Expenditure and certain Asset information regarding the company's geographical segments.



Veeda Clinical Research Private Limited

Notes to Standalone Financial Statements for the year ended March 31, 2019

Secondary Segment Reporting

(Amount in Rupees)

| Year ended 31 March 2019 | India | US | Greece | China | Others | Total |
|-------------------------------|-------------|-------------|-------------|-------------|-------------|---------------|
| Revenue from Operations | | | | | | |
| Sales to customers | 813,743,741 | 335,955,414 | 221,402,598 | 388,814,576 | 338,316,843 | 2,098,233,172 |
| Other segment information | | | | | | |
| Segment Assets | 897,796,971 | 39,719,497 | 75,236,625 | 93,473,566 | 108,751,362 | 1214,978,021 |
| Total Assets | | | | | | |
| Capital Expenditure: | | | | | | |
| Property, Plant and Equipment | 99,363,854 | | | | | 99,363,854 |
| Intangible Assets | 1,790,544 | | | | | 1,790,544 |

| Year ended 31 March 2018 | India | US | Greece | China | Others | Total |
|-------------------------------|-------------|-------------|-------------|-------------|-------------|---------------|
| Revenue from Operations | | | | | | |
| Sales to customers | 835,857,107 | 368,311,520 | 165,835,642 | 191,666,862 | 263,070,020 | 1,824,741,151 |
| Other segment information | | | | | | |
| Segment Assets | 960,881,639 | 59,110,535 | 62,964,146 | 56,765,046 | 39,713,906 | 1179,435,272 |
| Total Assets | | | | | | |
| Capital Expenditure: | | | | | | |
| Property, Plant and Equipment | 89,573,550 | | | | | 89,573,550 |
| Intangible Assets | 4,395,162 | | | | | 4,395,162 |

India geographical segment includes certain assets which are common to all the geographical segment (i.e. India, US, Greece & China). Segment Assets does not include deferred and income tax assets.

37. Details of CSR expenditure.

(Amount in Rupees)

| Particulars | For the year ending March 31, 2019 | | | For the year ending March 31, 2018 | | |
|---|------------------------------------|------------------------|-----------|------------------------------------|------------------------|-----------|
| | In cash | Yet to be paid in cash | Total | In cash | Yet to be paid in cash | Total |
| Gross amount required to be spent during the year | - | - | 4,778,522 | - | - | 2,130,533 |
| Amount spent during the year | 2,184,000 | - | 2,184,000 | 7,131,000 | - | 7,131,000 |
| Construction/acquisition of any asset | - | - | - | - | - | - |
| On purposes other than above | 2,184,000 | - | 2,184,000 | 7,131,000 | - | 7,131,000 |



38. Net dividend remitted in foreign exchange.

| Year of remittance (ending on) | March 31, 2019 | March 31, 2018 |
|--|----------------------------|----------------|
| Period to which it relates | 25 Oct 2008 to 30 Sep 2018 | - |
| Number of non-resident shareholders | 2 | - |
| Number of preference shares held on which dividend was due | 51,018 | - |
| Amount remitted (in USD) | 3,729,002 | - |
| Amount remitted (in INR) | 259,351,316 | - |


39. Prior period income

Export incentive income includes incentive of Rs. 31,538,584/- for which the application was made in the previous year, however income has been recognised in the current year.

40. Previous year figures have been re-grouped / re-arranged, wherever considered necessary to make them comparable with those of the current year. Previous year financial statements of the company were audited by Pradip R Shah & Co., Chartered Accountants, whose audit report dated June 15, 2018 expressed an unmodified opinion.

For SRBC & Co. LLP
Chartered Accountants
ICAI FRN: 324982E/E300003

For and on Behalf of the Board of Directors of
Veeda Clinical Research Private Limited
(CIN: U73100GJ2004PTC044023)


per Sukrut Mehta
Partner
Membership No. 101974
UDIN: 19101974AAAAAB8240


Vivek Chhachhi
Director
DIN: 00496620


Ajay Tandon
Executive Director
DIN: 02210072


Nirmal Bhatia
Company Secretary



Place: Ahmedabad
Date : July 25, 2019

Place: Delhi Delhi
Date : July 25, 2019 July 25, 2019

Ahmedabad
July 25, 2019

